CAMBRIDGE, Mass.--(BUSINESS WIRE)--
InVivo Therapeutics Holdings Corp. (NVIV) today announced the
appointment of Steven McAllister as Chief Financial Officer, effective
immediately. Mr. McAllister has been serving as InVivo’s Interim CFO
since December of 2013.
Mr. McAllister previously served as Vice President, Finance and
Administration for Biomet Spine and Bone Healing Technologies (a private
equity-owned medical device company) from 2007–2013, where he was
responsible for all accounting, finance, IT, facilities, and insurance
operations activities in addition to leading the company’s strategic
planning initiatives. Prior to Biomet, Mr. McAllister spent eight years
with Johnson & Johnson’s Medical Device and Diagnostics Group, where he
served as Director of Finance for the worldwide spine business, and
Director of Finance, Worldwide Operations, for Global Orthopedics. From
1984–1999 he worked in several capacities in Pfizer’s medical device
business, which was sold to Stryker in 1998. Mr. McAllister received his
BS in Accounting from Fairleigh Dickinson University.
Mark Perrin, InVivo’s Chief Executive Officer, said, “Steve McAllister
brings a wealth of experience in financial management. I value the
contributions he has made during this transitional period and I am
pleased to have him as part of the leadership team.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company
with unique technologies for drug delivery with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, ScD., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
is affiliated with Massachusetts General Hospital. In 2011 the Company
earned the David S. Apple Award from the American Spinal Injury
Association for its outstanding contribution to spinal cord injury
medicine. The publicly traded company is headquartered in Cambridge, MA.
For more details, visit, www.invivotherapeutics.com.
InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Source: InVivo Therapeutics Holdings Corp.